Rhythm reports Imcivree’s key weight loss data from Phase 2 Prader-Willi trialnews2025-12-11T16:17:38+00:00December 11th, 2025|Endpoints News|
AC Immune says early biomarker data are promising in Parkinson’s, but clinical benefit remains unclearnews2025-12-11T15:31:37+00:00December 11th, 2025|Endpoints News|
Zealand inks deal with OTR Therapeutics as it spells out broader metabolic disease ambitionsnews2025-12-11T12:12:44+00:00December 11th, 2025|Endpoints News|
Lilly’s triple agonist posts strongest weight loss data yet, unusual skin side effect also reportednews2025-12-11T11:45:15+00:00December 11th, 2025|Endpoints News|
#SABCS25: Roche’s breast cancer pill cuts post-surgery disease recurrence risk by 30%news2025-12-10T13:15:32+00:00December 10th, 2025|Endpoints News|
#ASH25: New data from Gilead, J&J set up a bispecific, CAR-T rivalrynews2025-12-09T19:17:45+00:00December 9th, 2025|Endpoints News|
#ASH25: Early in vivo CAR-T results like Kelonia’s elicit excitement across the fieldnews2025-12-09T16:04:26+00:00December 9th, 2025|Endpoints News|
#SABCS25: BioNTech, BMS unwrap Phase 2 data for PD-L1xVEGF-A bispecific in breast cancernews2025-12-09T12:31:42+00:00December 9th, 2025|Endpoints News|
#ASH25: Eli Lilly’s Jaypirca makes first-line case, but ceiling may be cappednews2025-12-09T12:30:47+00:00December 9th, 2025|Endpoints News|
#ASH25: Novartis says its antibody ianalumab helps prolong control of rare blood disordernews2025-12-09T12:30:30+00:00December 9th, 2025|Endpoints News|
